MX2018002322A - Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo. - Google Patents

Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo.

Info

Publication number
MX2018002322A
MX2018002322A MX2018002322A MX2018002322A MX2018002322A MX 2018002322 A MX2018002322 A MX 2018002322A MX 2018002322 A MX2018002322 A MX 2018002322A MX 2018002322 A MX2018002322 A MX 2018002322A MX 2018002322 A MX2018002322 A MX 2018002322A
Authority
MX
Mexico
Prior art keywords
crystalline forms
preparing
parp inhibitor
preparing parp
compound
Prior art date
Application number
MX2018002322A
Other languages
English (en)
Inventor
Zhou Changyou
Bo Ren
Hexiang Wang
Kuang Xianzhao
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2018002322A publication Critical patent/MX2018002322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar un inhibidor de Parp1/2, es decir, (R)-2-fluoro-10a-metil-7,8,9, 10, 10a, 11-hexahidro-5,6,7a,11-tetraazaciclohepta[def]ciclopenta[ a]fluoren-4(5H)-ona (en lo sucesivo, referido como compuesto A), formas cristalinas (polimorfos) del compuesto A o hidrato o solvato del mismo, métodos para preparar las formas cristalinas, y el uso de las mismas.
MX2018002322A 2015-08-25 2016-08-22 Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo. MX2018002322A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Publications (1)

Publication Number Publication Date
MX2018002322A true MX2018002322A (es) 2018-04-11

Family

ID=58099633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002322A MX2018002322A (es) 2015-08-25 2016-08-22 Procedimiento para la preparacion de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo.

Country Status (15)

Country Link
US (1) US10457680B2 (es)
EP (1) EP3341375B1 (es)
JP (1) JP6940039B2 (es)
KR (1) KR20180041748A (es)
CN (2) CN112521390A (es)
AU (1) AU2016312011B2 (es)
BR (1) BR112018003634B1 (es)
CA (1) CA2994895A1 (es)
EA (1) EA037366B1 (es)
IL (2) IL257442B2 (es)
MX (1) MX2018002322A (es)
NZ (1) NZ739876A (es)
TW (1) TWI736550B (es)
WO (1) WO2017032289A1 (es)
ZA (1) ZA201800765B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2797921T1 (en) 2011-12-31 2018-01-31 Beigene, Ltd. Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
WO2018059437A1 (en) * 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCER WITH A COMBINATION OF PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
WO2019220390A1 (en) * 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
TW202002985A (zh) * 2018-06-01 2020-01-16 英屬開曼群島商百濟神州有限公司 在胃癌治療中的parp抑制劑維持療法
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法
CN113402502B (zh) * 2019-05-16 2022-10-14 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体制备的物料组合体系
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
KR20220016028A (ko) * 2019-05-31 2022-02-08 베이진 엘티디 Parp 억제제 펠릿 제조 및 이의 제조방법
CN112007011A (zh) * 2019-05-31 2020-12-01 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302941B6 (cs) 1999-01-11 2012-01-25 Agouron Pharmaceuticals, Inc. Tricyklická sloucenina a farmaceutický prostredek s jejím obsahem
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
JP3990718B2 (ja) * 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
KR101846029B1 (ko) 2008-08-06 2018-04-06 메디베이션 테크놀로지즈 엘엘씨 폴리(ａｄｐ-리보오스)폴리머라아제 (ｐａｒｐ)의 디히드로피리도프탈라지논 억제제
SI2797921T1 (en) 2011-12-31 2018-01-31 Beigene, Ltd. Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
WO2018059437A1 (en) 2016-09-27 2018-04-05 Beigene, Ltd. Treatment cancers using combination comprising parp inhibitors
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCER WITH A COMBINATION OF PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法

Also Published As

Publication number Publication date
JP2018528199A (ja) 2018-09-27
KR20180041748A (ko) 2018-04-24
IL296835A (en) 2022-11-01
BR112018003634A2 (pt) 2018-11-21
CN107922425A (zh) 2018-04-17
BR112018003634B1 (pt) 2023-11-21
BR112018003634A8 (pt) 2023-01-17
AU2016312011A1 (en) 2018-03-08
EP3341375A1 (en) 2018-07-04
TWI736550B (zh) 2021-08-21
IL257442B (en) 2022-11-01
CN107922425B (zh) 2021-06-01
EA201890547A1 (ru) 2018-07-31
EP3341375A4 (en) 2019-01-16
WO2017032289A1 (en) 2017-03-02
US10457680B2 (en) 2019-10-29
JP6940039B2 (ja) 2021-09-22
ZA201800765B (en) 2019-10-30
AU2016312011B2 (en) 2021-02-04
IL257442A (en) 2018-04-30
US20190177325A1 (en) 2019-06-13
EA037366B1 (ru) 2021-03-18
EP3341375B1 (en) 2022-04-13
TW201718586A (zh) 2017-06-01
CN112521390A (zh) 2021-03-19
CA2994895A1 (en) 2017-03-02
NZ739876A (en) 2022-09-30
IL257442B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
NZ739876A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
WO2016011390A8 (en) Irak4 inhibiting agents
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
MX2018003284A (es) Compuestos antifungicos y procesos para hacerlos.
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
AU2015292632B2 (en) Aldosterone synthase inhibitors
EP3130592A4 (en) Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
JOP20190163B1 (ar) منشط nrf2
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
MX2019012765A (es) Proceso para la fabricacion de la forma alfa de vortioxetina hbr.
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
WO2015104602A3 (en) A process for the preparation of anagliptin and its intermediates thereof
MX2018015871A (es) Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc.
IN2014CH01257A (es)
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.